drugset / Trial / NCT00294788

Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines

NCT00294788 ↗

Phase 1/2 Unknown 300 enrolled Probiomics Ltd
RandomizedParallel-groupDouble-blindPrevention

Summary

This project aims to test the hypothesis that oral consumption of a specific strain of the probiotic bacterium Lactobacillus fermentum (trademarked PCC®) is able to significantly enhance the immune response to a vaccine for influenza.

Timeline

Start
2006-03
Primary completion
—
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus fermentum VRI 003 Other / unclassified — Oral
Background Fluvax Vaccine — —

Indications